Processing .....please wait.. 
The article has been forwarded.... 
Cadila Pharma launches new cardio drug
Wednesday, 10 September 2003, 19:30 IST
AHMEDABAD: Cadila Pharmaceuticals Limited (CPL) launched Nebivolol, a one-of-its-kind cardio drug here Tuesday, strengthening its position in the 
1.87 billion market for "beta blockers".
With CPL being the only bulk manufacturer of Nebivolol bulk in India, it expects a turnover of 60 million in the first year itself, senior vice president R. Sahni said.
Nebivolol helps set right the dysfunction in the inner layer of the blood vessel by restoring nitric oxide production, and providing a vasodilatory effect. This is not seen in any other "Beta-1 blocker", a company press release said.
The cardiovascular market in India is estimated at 6.850 billion and is growing at the rate of 8 percent.
Source: IANS
1.87 billion market for "beta blockers".
With CPL being the only bulk manufacturer of Nebivolol bulk in India, it expects a turnover of 60 million in the first year itself, senior vice president R. Sahni said.
Nebivolol helps set right the dysfunction in the inner layer of the blood vessel by restoring nitric oxide production, and providing a vasodilatory effect. This is not seen in any other "Beta-1 blocker", a company press release said.
The cardiovascular market in India is estimated at 6.850 billion and is growing at the rate of 8 percent.
Source: IANS